Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05394675 · ClinicalTrials.gov registry record · Phase 1
A Study of DS-9606a in Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by Daiichi Sankyo.
- Terminated
- Registry status
- Phase 1
- Development phase
- 88
- Enrollment target
NCT05394675: Clinical Trial Phase 1 study, sponsored by Daiichi Sankyo.
NCT05394675 is a Phase 1 study that was terminated before completion, run by Daiichi Sankyo. The registered enrollment target is 88 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (47% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05394675, a Phase 1 study, was terminated before completion, sponsored by Daiichi Sankyo.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 88 participants
- Enrollment target
Study Summary
This study will assess the safety and tolerability of DS-9606a in patients with advanced solid tumors.
Interventions
- DRUG DS-9606a
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2022-05-31 |
| Est. Completion | 2026-02-06 |
| Phase | Phase 1 |
Why NCT05394675 stopped before completion
NCT05394675 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 88 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (47% higher).
The record links to 0 conditions, and to 1 intervention - of which DS-9606a is the first listed.
NCT05394675 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05394675 about?
NCT05394675 is a clinical study titled "A Study of DS-9606a in Patients With Advanced Solid Tumors". This study will assess the safety and tolerability of DS-9606a in patients with advanced solid tumors.
What is the current status of trial NCT05394675?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 88 participants. The study started on 2022-05-31. Estimated completion is 2026-02-06.
What interventions are being tested in trial NCT05394675?
The interventions under investigation include: DS-9606a (DRUG).
Who is sponsoring clinical trial NCT05394675?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05394675's enrollment target sits among peer trials
88 650th of 2000 higher than 1,350 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03843463 · 88 participants · Phase 2
Escitalopram and Language Intervention for Subacute Aphasia
- NCT04066348 · 88 participants · Phase 2
TNF-α Treatment of Blast-Induced Tinnitus
- NCT04331704 · 88 participants · Phase 4
ANCHORS Alcohol & Sexual Health Study: UH3 Project
- NCT04536103 · 88 participants
Multi-Vendor Multi-Site Novel Accelerated MRI Relaxometry
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI